PDSP is a peptide drug molecule discovered by a research group at a medical center in Taiwan and BRIM has exclusive worldwide rights for PDSP program. PDSP possesses neurotrophic activities to enhance cell proliferation in wound healing and tissue regeneration. PDSP will be developed as topical and injectable products according to its clinical application and patient needs.
BRM421 is the project of developing PDSP for topical ophthalmic applications such as dry eye disease. BRM421 has demonstrated its efficacy in dry eye and corneal wound healing animal models. BRM421 can effectively repair corneal injury, and enhance proliferation of limbal epithelia stem cells in the mouse model. The IND-enabling package is under preparation and BRIM is planning to file the IND in the US by the end of 2016.
In addition to ophthalmic applications, PDSP was also evaluated for other uses in several animal models including muscle regeneration, osteoarthritis, androgenic alopecia. BRIM will initially focus on developing BRM421 for treating various ophthalmic diseases and subsequently evaluate applications in other therapeutic areas.